Recurrent Prostate Cancer Clinical Trial
Official title:
Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence
The investigators will perform a study with 25 patients in whom the investigators have a strong suspicion of prostate cancer that has returned to the body after having an initial treatment. The major goal of the investigation is to see whether anti-[18F] FACBC PET-CT and MRI imaging individually will be useful in the detection of local and extraprostatic recurrence of prostate cancer. Routine blood test will be done on the day of the FACBC scan and one week later as required by the FDA. All patients will undergo biopsy of the prostate as clinically appropriate per standard of care. If either the FACBC or MRI scans indicate cancer recurrence, the subject's cancer site(s) will also be biopsied as clinically appropriate.
Prostate cancer is the most common solid tumor, with approximately 200,000 new cases
diagnosed per year. Several different local therapies are available for treatment, including
surgery and radiotherapy. Significant advances have been made which have improved the cancer
control outcomes and treatment. Despite these significant advances, approximately 30% of
patients treated with definitive local therapy experience recurrent disease. Recurrent
(returning) disease usually displays rising Prostate-Specific Antigen (PSA) (a blood test for
prostate cancer). The PSA level is often of limited use in differentiating local recurrence
(i.e. recurrence in the prostate bed) from recurrence outside of the prostate bed
(extra-prostatic recurrence). Imaging plays a central role in the detection of recurrent
prostate carcinoma in the prostate bed and in the differentiation of prostatic from
extraprostatic recurrence. There are newer methods of imaging such as magnetic resonance
imaging (MRI) and positron emission tomography (PET) with molecular radiotracers that are
currently under study for the imaging of post-therapy recurrence.
One PET radiotracer which has shown promise in the staging and restaging of patients with
prostate carcinoma is anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid
(anti-3-[18F]FACBC) which is a synthetic amino acid analog. FACBC demonstrated higher
accuracy compared with other methods in the restaging of patients with suspected recurrent
prostate carcinoma. FACBC has been tested in over 140 subjects in other studies in the Emory
system including 128 subjects with prostate cancer.
The investigators will perform a study with 25 patients in whom the investigators have a
strong suspicion of prostate cancer that has returned to the body after having an initial
treatment. The major goal of the investigation is to see whether anti-[18F] FACBC PET-CT and
MRI imaging individually will be useful in the detection of local and extraprostatic
recurrence of prostate cancer. Routine blood test will be done on the day of the FACBC scan
and one week later as required by the FDA.
All patients will undergo biopsy of the prostate as clinically appropriate per standard of
care. If either the FACBC or MRI scans indicate cancer recurrence, the subject's cancer
site(s) will also be biopsied as clinically appropriate. Biopsy of the suspected recurrence
sites will be scheduled at the subjects' convenience as soon as possible after the scans.
Tissue obtained from the biopsy will undergo standard analysis to determine if prostate
carcinoma cells are present. The secondary aim is to use left-over biopsy material to
determine if there are genotypic differences between prostate carcinoma recurrence confined
to the prostate bed and extraprostatic recurrence
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT03718260 -
PSMA-PET Registry for Recurrent Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT01685125 -
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01054079 -
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
|
Phase 2 | |
Terminated |
NCT00512668 -
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
|
Phase 1 | |
Completed |
NCT00103194 -
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT00087139 -
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05304858 -
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
|
||
Completed |
NCT02250014 -
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01655836 -
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 1 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06070272 -
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
|
||
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01260688 -
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
|
Phase 2 | |
Completed |
NCT01682941 -
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
|
N/A | |
Completed |
NCT01220817 -
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
|
Phase 2 | |
Completed |
NCT00775866 -
MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy
|
N/A | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05044754 -
SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy
|
||
Active, not recruiting |
NCT01923506 -
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
|
Phase 1 |